Biocon Secures Health Canada Approval for Denosumab Biosimilars BOSAYA™ and VEVZUO™
MM Desk
22 April, 2026
Biocon Limited has received a Notice of Compliance (NOC) from Health Canada for its denosumab
Biocon Limited has received a Notice of Compliance (NOC) from Health Canada for its denosumab
Biocon Limited has announced the appointment of Shreehas Tambe as Chief Executive Officer and Managing
Biocon Limited (BSE: 532523 | NSE: BIOCON), a global biopharmaceutical company focused on innovation-driven therapies,
Biocon Biologics Ltd (BBL), a global, fully integrated biosimilars company and a subsidiary of Biocon
Ajanta Pharma Ltd, a specialty-focused pharmaceutical formulations company, has announced the signing of an in-licensing
Biocon Biologics Limited, a fully integrated global biosimilars company and a subsidiary of Biocon Limited,
Biocon Biologics Limited, a fully integrated global biosimilars company and a subsidiary of Biocon Limited,
Biocon Limited (BSE: 532523 | NSE: BIOCON), a global biopharmaceutical company driven by innovation, has
Biocon Biologics Ltd (BBL), a wholly owned subsidiary of Biocon Ltd (BSE: 532523, NSE: BIOCON),
Centum S&P Global Ratings has revised its outlook on Biocon Biologics Limited, moving the company